Alpelisib

Last Updated: 04/28/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 612 publications

PIK3CA mutant cervical cancer is selectively suppressed by PI3Kα inhibition (Alpelisib/BYL-719 and Inavolisib/GDC-0077) and cooperates with HPV directed T cell therapy.

PIK3CA mutant cervical cancer is selectively suppressed by PI3Kα inhibition (Alpelisib/BYL-719 and Inavolisib/GDC-0077) and cooperates with HPV directed T cell therapy.

Journal: Neoplasia (New York, N.Y.)
Published: April 01, 2026

Impact of Time of Administration, Fasting, and a Low-Carbohydrate Diet on Alpelisib-Associated Hyperglycemia and Efficacy: A Pilot Randomized Controlled Phase IIb Trial.

Impact of Time of Administration, Fasting, and a Low-Carbohydrate Diet on Alpelisib-Associated Hyperglycemia and Efficacy: A Pilot Randomized Controlled Phase IIb Trial.

Journal: Cancers
Published: February 27, 2026

Targeted Therapies in Infantile Hemangiomas and Vascular Malformations: From β-Blockers to PI3K/AKT/mTOR Inhibitors.

Targeted Therapies in Infantile Hemangiomas and Vascular Malformations: From β-Blockers to PI3K/AKT/mTOR Inhibitors.

Journal: Journal of cellular and molecular medicine
Published: February 15, 2026

A Three-subtype Molecular model of Cervical Cancer: Multiple PI3K Pathway inhibitors suppress growth and cooperate with HPV-directed immunotherapy.

A Three-subtype Molecular model of Cervical Cancer: Multiple PI3K Pathway inhibitors suppress growth and cooperate with HPV-directed immunotherapy.

Journal: medRxiv : the preprint server for health sciences
Published: February 06, 2026

Alpelisib-induced severe interstitial lung disease: case report.

Alpelisib-induced severe interstitial lung disease: case report.

Journal: Journal of chemotherapy (Florence, Italy)
Published: January 02, 2026

Comparison Between Alpelisib Plus Endocrine Therapy and Everolimus Plus Endocrine Therapy After CDK4/6 Inhibitors Progression in Patients with PIK3CA-Mutant Metastatic Breast Cancer: A Single-Center Retrospective Study.

Comparison Between Alpelisib Plus Endocrine Therapy and Everolimus Plus Endocrine Therapy After CDK4/6 Inhibitors Progression in Patients with PIK3CA-Mutant Metastatic Breast Cancer: A Single-Center Retrospective Study.

Journal: Cancers
Published: December 29, 2025

Comprehensive molecular analyses for diagnosis and treatment guidance in an adult neuroblastoma patient.

Comprehensive molecular analyses for diagnosis and treatment guidance in an adult neuroblastoma patient.

Journal: The oncologist
Published: December 23, 2025

Dual PI3K/mTOR inhibition is required to combat resistance to CDK4/6 inhibitor and endocrine therapy in PIK3CA-mutant breast cancer.

Dual PI3K/mTOR inhibition is required to combat resistance to CDK4/6 inhibitor and endocrine therapy in PIK3CA-mutant breast cancer.

Journal: Science translational medicine
Published: December 17, 2025

Molecular and Cell Biological Characterization of Patient-Derived Head and Neck Squamous Carcinoma Cell Lines.

Molecular and Cell Biological Characterization of Patient-Derived Head and Neck Squamous Carcinoma Cell Lines.

Journal: Cancer science
Published: December 04, 2025

Structure-Guided Design of a Highly Selective PI3Kα Inhibitor Overcoming Metabolic Dysregulation with Potent Anti-breast Cancer Efficacy.

Structure-Guided Design of a Highly Selective PI3Kα Inhibitor Overcoming Metabolic Dysregulation with Potent Anti-breast Cancer Efficacy.

Journal: Journal of medicinal chemistry
Published: November 17, 2025

Mapping the Kinase Inhibitor Landscape in Canine Mammary Carcinoma: Current Status and Future Opportunities.

Mapping the Kinase Inhibitor Landscape in Canine Mammary Carcinoma: Current Status and Future Opportunities.

Journal: Animals : an open access journal from MDPI
Published: November 14, 2025

Targeting CB1 and TRPM8 receptors to counteract CD8+ T cell exhaustion.

Targeting CB1 and TRPM8 receptors to counteract CD8+ T cell exhaustion.

Journal: Scientific reports
Published: November 13, 2025
Showing 1-12 of 612

Last Updated: 04/28/2026